Wockhardt shares add to their 220% gain for 2024 with another 10% surge — Explained

Wockhardt said that the drug, WCK 5222, is nearing the completion of its Phase III study for global registration and marketing authorisation.

Leave a Reply

Your email address will not be published. Required fields are marked *